Voyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Voyager Therapeutics (NASDAQ:VYGR) released its quarterly earnings results on Monday. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.06, Zacks reports. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%.

Voyager Therapeutics Stock Performance

Shares of VYGR traded up $0.03 during mid-day trading on Monday, hitting $4.26. 557,072 shares of the company’s stock were exchanged, compared to its average volume of 573,866. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $7.44. The company has a market cap of $236.30 million, a price-to-earnings ratio of -2.30 and a beta of 0.95. The stock’s 50-day moving average is $4.51 and its 200-day moving average is $3.71.

Insider Buying and Selling at Voyager Therapeutics

In other news, CFO Nathan D. Jorgensen sold 7,666 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the sale, the chief financial officer owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. This represents a 5.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Occudo Quantitative Strategies LP acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at about $78,000. Jane Street Group LLC increased its stake in shares of Voyager Therapeutics by 92.6% during the second quarter. Jane Street Group LLC now owns 27,844 shares of the company’s stock worth $87,000 after buying an additional 13,389 shares during the period. Invesco Ltd. raised its holdings in Voyager Therapeutics by 30.4% in the second quarter. Invesco Ltd. now owns 63,298 shares of the company’s stock valued at $197,000 after acquiring an additional 14,758 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Voyager Therapeutics in the first quarter worth approximately $218,000. Finally, American Century Companies Inc. lifted its stake in Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after acquiring an additional 6,748 shares during the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VYGR. Wedbush lowered their price target on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Voyager Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.96.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.